Phase II testing of ELND005 was completed in August 2010.
Primary outcome measures included cognition and function.
Safety and tolerability were also tested. See related Alzforum
News August 13, 2010 and Alzforum
News Dec 16, 2009.
Scyllo-inositol is a specific stereoisomer of the cyclic
sugar alcohol inositol, occurring naturally in coconut palm,
dogwood flowers and oak bark. McLaurin
et al 2006
showed that scyllo-inositol can inhibit aggregation of Aβ in
transgenic mice, improves many AD-like phenotypes and
protects from cognitive decline.
The Phase II trial completed the treatment of patients
receiving 250 mg twice daily dosing. Elan has reported the
study's cognitive (NTB) and functional (ADCS-ADL) co-primary
endpoints did not achieve statistical significance. However,
Elan reported that 250mg bid dose “demonstrated a
biological effect” on Aβ in the cerebrospinal fluid (CSF),
although no details have been provided. (See Elan
press release). Twenty subjects total
volunteered to provide CSF samples at beginning and end of
trial. CSF analysis provided evidence that the 250 mg bid
dose “achieved targeted drug levels in the CSF, and showed
some effects on clinical endpoints in an exploratory analysis”.